Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
FDA update could extend Hims & Hers’ compounding timeline, says BofA
BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...
Verywell Health on MSN2d
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer Program
Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
HealthTech Magazine2d
HIMSS25: Finding Clarity in Healthcare’s Digital Transformation
Health systems should ground their tech expectations in clear use cases and collaborative education, leaders shared at the ...
Security Info Watch1d
Study reveals how AI is reshaping commercial building management
A new Honeywell study highlights the growing adoption of AI in commercial buildings, emphasizing its impact on security, operational efficiency and energy management.
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
HealthTech Magazine6d
HIMSS25: Healthcare Needs More Cybersecurity Support in Staffing and Partnerships
That’s according to the 2024 HIMSS Healthcare Cybersecurity Survey report, released last month: 52% of respondents said that ...